These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26165720)

  • 1. On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.
    Vauquelin G
    Expert Opin Drug Discov; 2015 Oct; 10(10):1085-98. PubMed ID: 26165720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.
    Vauquelin G
    Br J Pharmacol; 2017 Dec; 174(23):4233-4246. PubMed ID: 28838028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems.
    Vauquelin G; Van Liefde I
    Expert Opin Drug Discov; 2012 Jul; 7(7):583-95. PubMed ID: 22650795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.
    Vauquelin G; Charlton SJ
    Br J Pharmacol; 2010 Oct; 161(3):488-508. PubMed ID: 20880390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.
    Vauquelin G
    Br J Pharmacol; 2016 Aug; 173(15):2319-34. PubMed ID: 27129075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time.
    Vauquelin G
    Expert Opin Drug Discov; 2010 Oct; 5(10):927-41. PubMed ID: 22823988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.
    Ploeger BA; van der Graaf PH; Danhof M
    Drug Metab Pharmacokinet; 2009; 24(1):3-15. PubMed ID: 19252332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models.
    Kapitulnik J; Pelkonen O; Gundert-Remy U; Dahl SG; Boobis AR
    Expert Opin Ther Targets; 2009 Jul; 13(7):867-87. PubMed ID: 19530989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Øie-Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior.
    Stepensky D
    Expert Opin Drug Metab Toxicol; 2011 Oct; 7(10):1233-43. PubMed ID: 21919805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.
    Smit C; De Hoogd S; Brüggemann RJM; Knibbe CAJ
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):275-285. PubMed ID: 29431542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
    Gibiansky L; Gibiansky E
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of drug distribution and drug-target binding on target occupancy: The rate-limiting step approximation.
    de Witte WEA; Vauquelin G; van der Graaf PH; de Lange ECM
    Eur J Pharm Sci; 2017 Nov; 109S():S83-S89. PubMed ID: 28502676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
    Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
    J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of the drug-target residence time model.
    Copeland RA
    Expert Opin Drug Discov; 2021 Dec; 16(12):1441-1451. PubMed ID: 34210223
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics and the drug-target residence time concept.
    Dahl G; Akerud T
    Drug Discov Today; 2013 Aug; 18(15-16):697-707. PubMed ID: 23500610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic insights from microfluidic intestine-on-a-chip models.
    Lee SH; Choi N; Sung JH
    Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):1005-1019. PubMed ID: 31794278
    [No Abstract]   [Full Text] [Related]  

  • 20. The importance of drug-target residence time.
    Zhang R; Monsma F
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.